HOME >> MEDICINE >> NEWS
New data provide further evidence of effectiveness of targeted delivery of Relenza and efficacy in both A&B strains

San Francisco, 28 September, 1999: The targeted delivery of Relenza results in high concentrations of the drug in the primary site of viral replication, the lungs, up to 24 hours after inhalation. It is also effective against A& B strain influenza, and reduces complications requiring antibiotics. These are the conclusions from three studies of Relenza (zanamivir), the new anti-flu treatment, being presented to physicians at a major anti-viral conference.

The data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 26-29, in San Francisco, USA, provide further evidence of the effectiveness of Relenza, and its highly targeted mode of administration, against both A & B strains of influenza.

Results from a laboratory study, presented at ICAAC1, showed that the inhalation of Relenza resulted in a high concentration of the drug in the lungs. These levels of the drug allow for continued anti-viral activity at the major site of viral replication and were retained up to 24 hours after a single 10mg inhaled dose. These data strongly support the use of an inhaled therapy that delivers its effect direct to the site of major viral replication.

A further benefit of the high concentrations achieved in the respiratory tract is that the possibility of development of resistance to the drug is reduced. Other influenza anti-virals have been of limited clinical use because the virus can often develop resistance to them rapidly.

The efficacy of the drug against influenza B was demonstrated by a meta-analysis of 220 patients, with confirmed B strain flu, from a total of 1,572 patients involved in five placebo-controlled studies. Using a regimen of 10mg twice daily (bid) for five days2, time to alleviation of symptoms (the primary endpoint) was reduced by 25 per cent to 4.5 days for those taking Relenza, down from 6.0 days for those on placebo.

The results of this analysis confirm the efficacy of Relenza in
'"/>

Contact: Jeremy Payne
jyp96669@glaxowellcome.co.uk
44-181-966-4719
CPR Worldwide
28-Sep-1999


Page: 1 2

Related medicine news :

1. Study provides new estimates of the causes of child mortality worldwide
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. End AIDS drug waiting lists, HIV care providers tell policymakers
4. Artery clearing system does not provide benefit for patients undergoing PCI
5. Newly identified gene cluster on mouse X chromosome provides insights into fertility
6. University of Washington joins new Autism Treatment Network to provide better medical services
7. Rat whisking may provide insight into debilitating eye disorder
8. Researchers hope monkeys can provide new insights into depression
9. AGI and USGS provide unique tsunami disaster relief
10. New ITN Scholars Program provides junior faculty opportunity to develop clinical trials expertise
11. Pegaptanib provides benefit for neovascular age-related macular degeneration

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: